Hereditary movement disorders;Hereditäre Bewegungsstörungen

Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz

Volumn 50, Issue 12, 2007, Pages 1524-1530

  Schulz, Jörg B ^a,b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Friedreich's ataxia; German Network of Hereditary Movement Disorders (GeNeMove); Hereditary dystonias; Hereditary spastic paraparesis; Huntington's disease; Spinocerebellar ataxias; Wilson's disease

Indexed keywords

ARTICLE; CLINICAL TRIAL; COMMUNITY CARE; GERMANY; HEALTH CARE DELIVERY; HUMAN; MEDICAL RESEARCH; MOTOR DYSFUNCTION; ORGANIZATION AND MANAGEMENT;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; COMMUNITY NETWORKS; DELIVERY OF HEALTH CARE; GERMANY; HUMANS; MOVEMENT DISORDERS;

EID: 37149036760     PISSN: 14369990     EISSN: 14371588     Source Type: Journal    
DOI: 10.1007/s00103-007-0387-3     Document Type: Article

References (28)

1. Campuzano V, Montermini L, Molto MD, et al. (1996) Friedreich's ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 271:1423-1427
2. Puccio H, Koenig M (2000) Recent advances in the molecular pathogenesis of Friedreich ataxia. Hum Mol Genet 9:887-892
3. Schulz JB, Dehmer T, Schols L, et al. (2000) Oxidative stress in patients with Friedreich ataxia. Neurology 55:1719-1721
4. Puccio H, Koenig M (2002) Friedreich ataxia: a paradigm for mitochondrial diseases. Curr Opin Genet Dev 12:272-277
5. Buyse G, Mertens L, Di Salvo G, et al. (2003) Idebenone treatment in Friedreich's ataxia: neurological, cardiac, and biochemical monitoring. Neurology 60:1679-1681
6. Rustin P (2003) The use of antioxidants in Friedreich' s ataxia treatment. Expert Opin Investig Drugs 12:569-575
7. Schöls L, Bauer P, Schmidt T, et al. (2004) Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurology 3:291-304
8. Evert BO, Araujo J, Vieira-Saecker AM, et al. (2006) Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation. J Neurosci 26:11474-11486
9. Evert BO, Vogt IR, Vieira-Saecker AM, et al. (2003) Gene expression profiling in ataxin-3 expressing cell lines reveals distinct effects of normal and mutant ataxin-3. J Neuropathol Exp Neurol 62:1006-1018
10. Fink JK (2006) Hereditary spastic paraplegia. Current neurology and neuroscience reports 6:65-76
11. Sauter S, Miterski B, Klimpe S, et al. (2002) Mutation analysis of the spastin gene (SPG4) in patients in Germany with autosomal dominant hereditary spastic paraplegia. Human mutation 20:127-132
12. Albanese A, Barnes MP, Bhatia KP, et al. (2006) A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. European Journal of Neurology 13:433-444
13. Müller J, Kiechl S, Wenning GK, et al. (2002) The prevalence of primary dystonia in the general community. Neurology 59:941-943
14. Zimprich A, Grabowski M, Asmus F, et al. (2001). Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet 29:66-69
15. Nolte D, Niemann S, Muller U (2003) Specific sequence changes in multiple transcript system DYT3 are associated with X-linked dystonia parkinsonism. PNAS 100:10347-10352
16. Kupsch A, Benecke R, Muller J, et al. (2006) Pallidal deep-brain stimulation in primary generalized or segmental dystonia. N Engl J Med 355, 1978-1990
17. Walker FO (2007) Huntington's disease. Lancet 369:218-228
18. Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-983
19. Ala A, Walker AP, Ashkan K, et al. (2007) Wilson's disease. Lancet 369:397-408
20. Pulst SM, Nechiporuk A, Nechiporuk T, et al. (1996) Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet 14:269-276
21. von Hörsten S, Schmitt I, Nguyen HP, et al. (2003). Transgenic rat model of Huntington's disease. Hum Mol Genet 12:617-624
22. Schöls L, Amoiridis G, Büttner T, et al. (1997) Autosomal dominant cerebellar ataxia: phenotypic differences in genetically defined subtypes? Ann Neurol 42:924-932
23. Klockgether T, Ludtke R, Kramer B, et al. (1998) The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain 121:589-600
24. Klockgether T, Skalej M, Wedekind D, et al. (1998) Autosomal dominant cerebellar ataxia type I: MRIbased volumetry of posterior fossa structures and basal ganglia in SCA1, SCA2, and SCA3. Brain 121:1687-1693
25. Schulz JB, Dehmer T, Schöls L, et al. (2000) Oxidative stress in patients with Friedreich ataxia. Neurology 55:1719-1721
26. Schüle R, Holland-Letz T, Klimpe S, et al. (2006) The Spastic Paraplegia Rating Scale (SPRS): a reliable and valid measure of disease severity. Neurology 67:430-434
27. Schmitz-Hübsch T, du Montcel ST, Baliko L, et al. (2006). Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66:1717-1720
28. Schmitz-Hübsch T, Tezenas du Montcel S, Baliko L, et al. (2006) Reliability and validity of the International Cooperative Ataxia Rating Scale: a study in 156 spinocerebellar ataxia patients. Mov Disord 21:699-704